Ceftolozane-tazobactam pharmacokinetics during extracorporeal membrane oxygenation in a lung transplant recipient

Abstract

Ceftolozane-tazobactam pharmacokinetics during extracorporeal membrane oxygenation (ECMO) has not been previously studied. In this work we report on the ceftolozane and tazobactam plasmatic levels in a lung transplant recipient during ECMO, treated with ceftolozane-tazobactam (2g/1g, intravenously every 8 h, 1 h infusion) for a Pseudomonas aeruginosa pulmonary infection. Ceftolozane Cmax and Cmin, monitored during 96 hrs, remained above 60 and 20 g/mL, respectively, with optimal drug exposure (100% %TMIC). Tazobactam levels were above 1.9 g/mL.